Abstract
This article contains first person accounts in narrative and visual form created by clients and family members who have participated in the Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP). By the time most individuals join EDIPPP they have been experiencing a confusing constellation of thought and behavior changes. For most, EDIPPP signifies the next step in a journey of trying to reclaim a sense of agency in their lives and promise for the future. Understanding the process youth and families go through to make meaning of a “high risk” indication is critical for the clinicians who work with these families. By highlighting these first person accounts and the story they tell, we strive to contribute to this understanding and thereby enrich our discussion of the early detection and intervention for psychosis with the perspectives of individuals participating in our study. These narratives point to the potential value of further research focused specifically on how youth and families come to understand being at risk for psychosis.
Keywords: Adolescents, first person accounts, psychosis, schizophrenia, prodromal psychosis, high risk, recovery
Adolescent Psychiatry
Title:In the First Person: A Window into the Experience of Early Psychosis and Recovery
Volume: 2 Issue: 2
Author(s): Margaret Migliorati, Melina Salvador, Elizabeth Spring-Nichols, Sarah Lynch Tamara Sale and Steven Adelsheim
Affiliation:
Keywords: Adolescents, first person accounts, psychosis, schizophrenia, prodromal psychosis, high risk, recovery
Abstract: This article contains first person accounts in narrative and visual form created by clients and family members who have participated in the Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP). By the time most individuals join EDIPPP they have been experiencing a confusing constellation of thought and behavior changes. For most, EDIPPP signifies the next step in a journey of trying to reclaim a sense of agency in their lives and promise for the future. Understanding the process youth and families go through to make meaning of a “high risk” indication is critical for the clinicians who work with these families. By highlighting these first person accounts and the story they tell, we strive to contribute to this understanding and thereby enrich our discussion of the early detection and intervention for psychosis with the perspectives of individuals participating in our study. These narratives point to the potential value of further research focused specifically on how youth and families come to understand being at risk for psychosis.
Export Options
About this article
Cite this article as:
Migliorati Margaret, Salvador Melina, Spring-Nichols Elizabeth, Tamara Sale Sarah Lynch and Adelsheim Steven, In the First Person: A Window into the Experience of Early Psychosis and Recovery , Adolescent Psychiatry 2012; 2 (2) . https://dx.doi.org/10.2174/2210676611202020146
DOI https://dx.doi.org/10.2174/2210676611202020146 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy New Approaches for the Treatment of Mental Disorders Comorbid with Inflammatory Diseases
Current Topics in Medicinal Chemistry Diagnosis of Neurodegenerative Diseases: The Clinical Approach
Current Alzheimer Research Finding Drug Targets Through Analysis of the Platelet Transcriptome
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design Securinine Derivatives as Potential Anti-amyloid Therapeutic Approach
CNS & Neurological Disorders - Drug Targets Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Bioactivity of New μ and δ Opioid Peptides
Medicinal Chemistry Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design Can the Sigma-1 Receptor Agonist Fluvoxamine Prevent Schizophrenia?
CNS & Neurological Disorders - Drug Targets Modulation of Matrix Metalloproteinase Activity by Tobacco Cigarette Smoke
Current Chemical Biology Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Multi-particulate Systems: Cutting-edge Technology for Controlled Drug Delivery
Recent Patents on Drug Delivery & Formulation Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter?
Current Stem Cell Research & Therapy The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy